Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Cediranib
Synonyms
Therapy Description	Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778, PMID: 32444417).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Cediranib		AZD-2171\|Recentin\|AZD2171\|AZD 2171	KIT Inhibitor 57 VEGFR1 Inhibitor 6 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6	Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778, PMID: 32444417).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 14 of 14 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR2 amp	stomach cancer	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 30045926).	30045926
FGFR2 K660E	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).	23786770
FGFR2 K660N	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).	23786770
FGFR2 W290C	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).	23786770
FGFR1 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of estrogen receptor (ER)-positive breast cancer cells with FGFR1 amplification in culture (PMID: 22238366).	22238366
FGFR2 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR2 amp	colon cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2 amp	stomach cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2 N549K	endometrial cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).	22238366
FGFR2 S252W	endometrial cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).	22238366
FGFR3 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR3 S249C	urinary bladder cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).	22238366
FGFR3 Y375C	urinary bladder cancer	resistant	Cediranib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring an FGFR3 Y375C mutation were resistant to growth inhibition by Cediranib (AZD-2171) in culture (PMID: 22238366).	22238366

Showing 1 to 14 of 14 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 5 of 5 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01391962	Phase II	Sunitinib Cediranib	Sunitinib or Cediranib for Alveolar Soft Part Sarcoma	Active, not recruiting	USA	0
NCT02502266	Phase II	Topotecan Paclitaxel Doxorubicin Olaparib Cediranib	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	USA \| CAN	3
NCT00942877	Phase II	Cediranib	Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma	Completed	USA	0
NCT01208051	Phase Ib/II	Cediranib + Lenalidomide Cediranib	Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer	Completed	USA \| CAN	0
NCT03741426	Phase II	Durvalumab Cediranib Durvalumab + Olaparib Cediranib + Olaparib Olaparib	WIRE - Novel Treatments in Renal Cell Cancer (WIRE)	Recruiting	GBR	0

Showing 1 to 5 of 5 entries

Filter rows:

Additional content available in CKB BOOST